CONMED’s first quarter results were shaped by the company’s strategic exit from its gastroenterology (GI) product lines, which reduced reported sales but allowed management to spotlight growth in its remaining core platforms. CEO Patrick Beyer emphasized that, excluding the impact of the GI exit, CONMED saw continued progress in orthopedics and minimally invasive surgery, citing BioBrace’s clinical adoption and expanding AirSeal penetration as key contributors. Management noted, “Our decision was intentional and strategic. It allows us to concentrate resources and investment on our higher growth, higher-margin offerings.”
Is now the time to buy CNMD? Find out in our full research report (it’s free for active Edge members).
CONMED (CNMD) Q1 CY2026 Highlights:
- Revenue: $317 million vs analyst estimates of $310.5 million (1.3% year-on-year decline, 2.1% beat)
- Adjusted EPS: $0.89 vs analyst estimates of $0.82 (8.8% beat)
- Adjusted EBITDA: $56.39 million vs analyst estimates of $55.59 million (17.8% margin, 1.4% beat)
- The company slightly lifted its revenue guidance for the full year to $1.36 billion at the midpoint
- Management reiterated its full-year Adjusted EPS guidance of $4.38 at the midpoint
- Operating Margin: 8%, up from 5% in the same quarter last year
- Constant Currency Revenue rose 2.9% year on year, in line with the same quarter last year
- Market Capitalization: $1.10 billion
While we enjoy listening to the management's commentary, our favorite part of earnings calls are the analyst questions. Those are unscripted and can often highlight topics that management teams would rather avoid or topics where the answer is complicated. Here is what has caught our attention.
Our Top 5 Analyst Questions From CONMED’s Q1 Earnings Call
- Gracia Mahoney (Bank of America): Asked about the debt refinancing strategy and how CONMED plans to mitigate potential EPS dilution. CFO advisor Todd Garner explained that refinancing will use bank debt instead of convertible notes due to low med tech multiples, and the higher interest expense will be offset by underlying business strength.
- Gracia Mahoney (Bank of America): Raised concerns about inflation’s impact on margins. CEO Patrick Beyer responded that commodity cost pressures are present but manageable, and any macro effects are already included in margin guidance.
- Ross Osborn (Wells Fargo): Inquired about AirSeal’s attach rate to DV5 robotic systems. CEO Beyer confirmed the rate remains within the guided 10–20% range.
- Ross Osborn (Wells Fargo): Asked about the visibility of new state smoke evacuation legislation as a tailwind. Beyer highlighted 20 states have enacted laws, several more have pending bills, and legislative progress is factored into guidance.
- Robert Marcus (JPMorgan): Sought clarification on what drives the anticipated step-up in second-quarter revenue. CEO Beyer and CFO advisor Garner pointed to accelerating growth in orthopedics, increased AirSeal capital sales, and improved international performance as the primary contributors.
Catalysts in Upcoming Quarters
In coming quarters, the StockStory team will focus on (1) the pace of AirSeal adoption in U.S. laparoscopic and robotic surgery, (2) ongoing legislation and hospital uptake of Buffalo Filter smoke evacuation solutions, and (3) the expansion of BioBrace in new soft tissue applications. Progress in supply chain reliability and execution of the GI divestiture transition will also be key markers for sustained growth.
CONMED currently trades at $36.63, up from $35.96 just before the earnings. Is there an opportunity in the stock?The answer lies in our full research report (it’s free).
The Best Stocks for High-Quality Investors
ALSO WORTH WATCHING: Top 5 Momentum Stocks. The best time to own a great stock is when the market is finally noticing it. These aren't just high-quality businesses. Something is happening with them right now. Elite fundamentals meeting near-term momentum - both boxes checked at the same time.
Find out which stocks our AI platform is flagging this week. See this week's Strong Momentum stocks - FREE. Get Our Strong Momentum Stocks for Free HERE.
Stocks that have made our list include now familiar names such as Nvidia (+1,326% between June 2020 and June 2025) as well as under-the-radar businesses like the once-small-cap company Comfort Systems (+782% five-year return). Find your next big winner with StockStory today.